Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment - the COMPAS study
Open Access
- 4 September 2013
- journal article
- clinical trial
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 407
Abstract
It is known that suboptimal adherence rates may affect endocrine treatments for breast cancer, but little information has been reported whether any efforts to improve treatment adherence have been successful. We designed a randomized, controlled study to investigate the effect of oral or written patient information program on adherence and persistence when receiving an aromatase inhibitor (AI).Keywords
This publication has 31 references indexed in Scilit:
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancerBreast Cancer Research and Treatment, 2010
- Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapyCritical Reviews in Oncology/Hematology, 2010
- Adherence with adjuvant hormonal therapy for breast cancerAnnals of Oncology, 2009
- Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancerAnnals of Oncology, 2009
- Practical guidance for the management of aromatase inhibitor-associated bone lossAnnals of Oncology, 2008
- Using motivational interviewing to promote adherence to antiretroviral medications: A randomized controlled studyAIDS Care, 2008
- Early discontinuation of tamoxifenCancer, 2007
- Adherence to tamoxifen over the five-year courseBreast Cancer Research and Treatment, 2006
- Adherence to MedicationNew England Journal of Medicine, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004